About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

UNKNOWNNCT02330458

The Role of Small Bowel Ultrasound in Initiation of Infliximab in Crohn's Disease Patients

Goal is to prospectively determine if stool calprotectin and change in bowel wall thickness and hyperemia, as seen on small bowel ultrasound, at week 0, 14, and 54 can be used to predict response at w...

Lead sponsor: Cedars-Sinai Medical Center•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Cedars-Sinai Medical Center

We will examine whether non-invasive disease monitoring tools such as bowel wall thickness as measured by small bowel ultrasound (SBUS) and mucosal inflammation as measured by fecal calprotectin, are independently associated with infliximab durability.

Age

6 - 23 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Age 6-23 years
•Initiating Infliximab therapy
•Crohns disease involving the distal small bowel +/- proximal colon
•Willingness to undergo SBUS and fecal calprotectin collection prior to starting infliximab and again at week 14 and week 54
•Able to give consent by patient and/or legal guardian

Exclusion Criteria

•Ulcerative colitis or non-Crohn's Disease patients
•Lack of small bowel disease
•Patients started on alternative therapy
•Unable or unwilling to provide consent

Related studies

RECRUITINGPhase 3

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

NCT04844606 · Ulcerative Colitis, Ulcerative Colitis Chronic, and more

RECRUITINGEARLY Phase 1

A Clinical Study of SPH7854 Granules in Healthy Subjects.

NCT06483373 · Inflammatory Bowel Disease

RECRUITINGPhase 4

Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.

NCT06180382 · Crohn's Disease

Exploring Fecal Calprotectin Levels, Maternal and Infant Microbiota, Infant Health, Nutrition, and Adverse Pregnancy Outcomes With Patient With Inflammatory Bowel Disease

NCT07385807 · IBD (Inflammatory Bowel Disease), IBD, and more

RECRUITINGPhase 2

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

NCT06226883 · Inflammatory Bowel Diseases, Crohn's Disease

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: July 19, 2017Terms

Trial snapshot

StatusUNKNOWN

Phase—

Enrollment20

Start dateJul 2014

Last updatedJul 19, 2017

Condition

Inflammatory Bowel Disease Crohn's Disease

Locations shown

Cedars-Sinai Medical Center

Los Angeles, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 19, 2017Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions